Scinai Immunotherapeutics Ltd. (SCNI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Apr 1, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SCNI SEC filings page.
Scinai Immunotherapeutics Ltd. (SCNI) reported $1.3M in revenue for fiscal year 2025, up 99.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business remains development-stage: revenue is growing, but gross losses and recurring cash needs still require external financing.
FY2024’s accounting profit of$4.8M did not represent cash conversion: operating cash flow was-$6.3M ; FY2025 then returned to a net loss of$8.3M while cash outflow remained-$6.0M . The pattern points to earnings being affected by non-operating or non-cash items rather than a self-funding operating model.
Revenue roughly doubled from FY2024 to FY2025, yet the gross loss widened from
In FY2025, R&D was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Scinai Immunotherapeutics Ltd.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Scinai Immunotherapeutics Ltd. held $1.7M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $6.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Scinai Immunotherapeutics Ltd. scores 14/100 among other emerging companies.
Scinai Immunotherapeutics Ltd. had 13.87B shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Scinai Immunotherapeutics Ltd. scores 7/100 among other emerging companies.
Scinai Immunotherapeutics Ltd. spent $2.4M on research and development in fiscal year 2025, which was 26.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Scinai Immunotherapeutics Ltd. scores 59/100 among other emerging companies.
Scinai Immunotherapeutics Ltd. reported revenue of $1.3M in fiscal year 2025, against $658K in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Scinai Immunotherapeutics Ltd. scores 86/100 among other emerging companies.
Scinai Immunotherapeutics Ltd.'s operations used $6.0M of cash in fiscal year 2025, against $6.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Scinai Immunotherapeutics Ltd. scores 64/100 among other emerging companies.
Scinai Immunotherapeutics Ltd.'s cash, cash equivalents and investments came to $1.7M at the end of fiscal year 2025, against $3.5M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Scinai Immunotherapeutics Ltd. scores 43/100 among other emerging companies.
Scinai Immunotherapeutics Ltd. scores -16.99, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($820K) relative to total liabilities ($3.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Scinai Immunotherapeutics Ltd. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Scinai Immunotherapeutics Ltd. reported a net loss of $8.3M while operations used $6.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Scinai Immunotherapeutics Ltd. held $1.7M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
SCNI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q2'256-K | Q4'2420-F | Q2'2410-Q | Q4'2310-K | Q2'2310-Q | Q1'2310-Q | Q4'2210-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | $1.5M-26.3% | $2.0M+71.5% | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | $1.1M-11.5% | $1.2M-18.0% | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | -$2.6M+20.5% | -$3.2M-21.8% | N/A |
| EBITDA | N/A | N/A | N/A | N/A | N/A | -$2.4M+21.5% | -$3.0M-22.9% | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A | -$3.8M-26.1% | -$3.5M-42.0% | N/A |
| EPS (Basic) | N/A | N/A | N/A | N/A | N/A | $0.00+25.0% | $0.000.0% | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | $0.00 | $0.000.0% | N/A |
| Diluted Shares (Avg) | N/A | N/A | N/A | N/A | N/A | 1.35B | 1.30B+73.9% | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
SCNI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q2'256-K | Q4'2420-F | Q2'2410-Q | Q4'2310-K | Q2'2310-Q | Q1'2310-Q | Q4'2210-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.6M-13.5% | $11.8M-20.3% | $13.4M-23.0% | $14.9M-25.4% | $17.5M-35.4% | $19.9M | $23.3M | $27.1M-15.5% |
| Current Assets | $2.1M-14.1% | $1.5M-58.8% | $2.4M-56.1% | $3.7M-52.9% | $5.4M-62.1% | $7.8M | $11.0M | $14.4M-19.5% |
| Cash & Equivalents | $1.7M-15.4% | $989K-67.8% | $2.0M-59.7% | $3.1M-59.0% | $4.9M-65.4% | $7.5M-33.5% | $10.8M-29.8% | $14.1M-19.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $73K-12.0% | $139K+16.8% | $83K | $119K | N/A | N/A | N/A | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.5M+1.5% | $4.0M-82.0% | $3.5M-84.3% | $22.1M-18.0% | $22.0M-23.5% | $27.0M | $28.1M | $28.8M-7.2% |
| Current Liabilities | $1.6M-12.2% | $2.1M+26.8% | $1.8M+1.5% | $1.7M-11.4% | $1.8M-23.9% | $1.9M | $2.6M | $2.3M-4.3% |
| Non-Current Liabilities | $1.9M+16.4% | $1.9M-90.9% | $1.7M-91.8% | $20.5M-18.5% | $20.3M-23.5% | $25.1M | $25.5M | $26.5M-7.4% |
| Total Equity | $8.1M-18.8% | $7.9M+207.9% | $10.0M+318.4% | -$7.3M-2.4% | -$4.6M-159.6% | -$7.1M-317.9% | -$4.8M-458.0% | -$1.8M-279.2% |
| Retained Earnings | -$125.8M-7.1% | -$121.7M+4.1% | -$117.5M+3.9% | -$126.8M-3.0% | -$122.3M-5.6% | -$123.1M | -$119.3M | -$115.8M-5.3% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
SCNI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q2'256-K | Q4'2420-F | Q2'2410-Q | Q4'2310-K | Q2'2310-Q | Q1'2310-Q | Q4'2210-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A | -$2.9M+21.5% | -$3.1M-176.8% | N/A |
| Depreciation & Amortization | N/A | N/A | N/A | N/A | N/A | $147K+1.4% | $138K+3.0% | N/A |
| Stock-Based Compensation | N/A | N/A | N/A | N/A | N/A | N/A | $252K-48.0% | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $377K+977.1% | $6K-98.8% | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$3.3M+12.1% | -$3.1M-88.5% | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | -$377K-1177.1% | -$6K+98.8% | N/A |
Not reported in any period shown, so not listed: Financing Cash Flow, Dividends Paid, Share Buybacks.
SCNI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Scinai Immunotherapeutics Ltd. SCNI | FY2025 | $1.3M | -$8.3M | N/A | $820K | 46/100 |
| GT Biopharma Inc. GTBP | FY2025 | N/A | -$28.4M | N/A | $11.2M | — |
| Virax Biolabs Group Limited VRAX | FY2026 | $12K | -$5.0M | N/A | $1.7M | — |
| Psyence Biomedical Ltd. PBM | FY2026 | N/A | -$6.9M | N/A | $18.6M | — |
| LIPELLA PHARMS INC LIPO | FY2024 | $536K | -$5.0M | N/A | $11.8M | — |
| Salarius Pharmaceuticals, Inc. SLRX | FY2025 | N/A | $12.5M | N/A | $4.9M | — |
Where Scinai Immunotherapeutics Ltd. Ranks
Frequently Asked Questions
What is Scinai Immunotherapeutics Ltd.'s annual revenue?
Scinai Immunotherapeutics Ltd. (SCNI) reported $1.3M in total revenue for fiscal year 2025. This represents a 99.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Scinai Immunotherapeutics Ltd.'s revenue growing?
Scinai Immunotherapeutics Ltd. (SCNI) revenue grew by 99.2% year-over-year, from $658K to $1.3M in fiscal year 2025.
Is Scinai Immunotherapeutics Ltd. profitable?
No, Scinai Immunotherapeutics Ltd. (SCNI) reported a net income of -$8.3M in fiscal year 2025.
What is Scinai Immunotherapeutics Ltd.'s EBITDA?
Scinai Immunotherapeutics Ltd. (SCNI) had EBITDA of -$6.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Scinai Immunotherapeutics Ltd.'s return on equity (ROE)?
Scinai Immunotherapeutics Ltd. (SCNI) has a return on equity of -102.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Scinai Immunotherapeutics Ltd.'s free cash flow?
Scinai Immunotherapeutics Ltd. (SCNI) recorded an outflow of $6.1M in free cash flow during fiscal year 2025. This represents a 4.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Scinai Immunotherapeutics Ltd.'s operating cash flow?
Scinai Immunotherapeutics Ltd. (SCNI) recorded an outflow of $6.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Scinai Immunotherapeutics Ltd.'s total assets?
Scinai Immunotherapeutics Ltd. (SCNI) had $11.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Scinai Immunotherapeutics Ltd.'s capital expenditures?
Scinai Immunotherapeutics Ltd. (SCNI) invested $24K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Scinai Immunotherapeutics Ltd. spend on research and development?
Scinai Immunotherapeutics Ltd. (SCNI) invested $2.4M in research and development during fiscal year 2025.
What is Scinai Immunotherapeutics Ltd.'s current ratio?
Scinai Immunotherapeutics Ltd. (SCNI) had a current ratio of 1.30 as of fiscal year 2025, which is considered adequate.
What is Scinai Immunotherapeutics Ltd.'s debt-to-equity ratio?
Scinai Immunotherapeutics Ltd. (SCNI) had a debt-to-equity ratio of 0.43 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Scinai Immunotherapeutics Ltd.'s return on assets (ROA)?
Scinai Immunotherapeutics Ltd. (SCNI) had a return on assets of -71.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Scinai Immunotherapeutics Ltd.'s P/E ratio?
Scinai Immunotherapeutics Ltd. (SCNI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $820K as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Scinai Immunotherapeutics Ltd.'s price-to-sales ratio?
Scinai Immunotherapeutics Ltd. (SCNI) trades at 0.6x sales, its market capitalization divided by revenue of $1.3M revenue, FY2025. The market capitalization is $820K as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Scinai Immunotherapeutics Ltd.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Scinai Immunotherapeutics Ltd. (SCNI) held $1.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.0M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Scinai Immunotherapeutics Ltd.'s Altman Z-Score?
Scinai Immunotherapeutics Ltd. (SCNI) has an Altman Z-Score of -16.99, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Scinai Immunotherapeutics Ltd.'s Piotroski F-Score?
Scinai Immunotherapeutics Ltd. (SCNI) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Scinai Immunotherapeutics Ltd.'s earnings high quality?
Scinai Immunotherapeutics Ltd. (SCNI) reported a net loss of $8.3M while operations used $6.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Scinai Immunotherapeutics Ltd.?
Scinai Immunotherapeutics Ltd. (SCNI) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.